Quantification of high-density lipoprotein particle number by proton nuclear magnetic resonance: don't believe the numbers [0.03%]
氢质子核磁共振测定高密度脂蛋白颗粒数量：别信数字
Tomas Vaisar,Jay Heinecke
Tomas Vaisar
Purpose of review: Proton nuclear magnetic resonance (NMR) can rapidly assess lipoprotein concentrations and sizes in biological samples. It may be especially useful for quantifying high-density lipoprotein (HDL), which e...
Charlotte C Ellberg,Harpreet S Bhatia
Charlotte C Ellberg
Purpose of review: There is growing literature that supports the testing of Lp(a). However, few patients are tested, including those with a personal or family history of cardiovascular disease (CVD). One often noted barri...
Are the lipid-lowering effects of incretin-based therapies relevant for cardiovascular benefit? [0.03%]
基于肠降糖素的治疗的降脂作用与心血管收益有关吗？
Teba Alnima,Mark M Smits,Nordin M J Hanssen
Teba Alnima
Purpose of review: This review examines the impact of glucagon-like peptide 1 receptor agonists (GLP-1RAs) on lipid profiles in individuals with type 2 diabetes mellitus and/or obesity, crucial for optimizing cardiovascul...
Dawoud Sulaiman,Srinivasa T Reddy,Alan M Fogelman
Dawoud Sulaiman
Purpose of review: To review recent publications linking the intestine to cardiovascular disease. Recent findings: Aromatic amino acid-...
Proprotein convertase subtilisin/kexin type 9 as a drug target for abdominal aortic aneurysm [0.03%]
蛋白酶亚型9作为治疗腹主动脉瘤的新药物靶点
Jonathan Golledge,Hong S Lu,Sonia Shah
Jonathan Golledge
Purpose of review: There are no current drug therapies to limit abdominal aortic aneurysm (AAA) growth. This review summarizes evidence suggesting that inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) may ...
Complex actions of sodium glucose transporter-2 inhibitors on lipids, calcific atherosclerosis, and bone density [0.03%]
钠葡萄糖协同转运蛋白2抑制剂对脂质、钙化动脉粥样硬化和骨密度的复杂作用
Stuti Pradhan,Sophia Kalanski,Yin Tintut et al.
Stuti Pradhan et al.
Purpose of review: Inhibitors of sodium-glucose cotransporter-2 (SGLT2) lower renal glucose reabsorption and, thus, are used to treat patients with type 2 diabetes mellitus. Clinical trials coincidentally showed that SGLT...
Paraoxonase 1: evolution of the enzyme and of its role in protecting against atherosclerosis [0.03%]
关于丝氨酸酶卵磷脂胆固醇酰基转移酶在抵抗动脉粥样硬化中的进化及其作用的评论文章
Paul Durrington,Handrean Soran
Paul Durrington
Purpose of review: To review the discoveries which led to the concept that serum paraoxonase 1 (PON1) is inversely related to atherosclerotic cardiovascular disease (ASCVD) incidence, how this association came to be regar...
Pancreatic and cardiometabolic complications of severe hypertriglyceridaemia [0.03%]
严重高甘油三酯血症的胰腺和心血管代谢并发症
Bilal Bashir,Maryam Ferdousi,Paul Durrington et al.
Bilal Bashir et al.
Purpose of review: This review endeavours to explore the aetiopathogenesis and impact of severe hypertriglyceridemia (SHTG) and chylomicronaemia on cardiovascular, and pancreatic complications and summarizes the novel pha...
Familial hypercholesterolemia-Plus: is the metabolic syndrome changing the clinical picture of familial hypercholesterolemia? [0.03%]
代谢综合征会改变家族性高胆固醇血症的临床表现吗？
Liam R Brunham
Liam R Brunham
Purpose of review: The purpose of this review article was to describe recent advances in our knowledge about how diabetes and metabolic syndrome are changing the face of familial hypercholesterolemia. ...
Fernando Civeira,César Martín,Ana Cenarro
Fernando Civeira
Purpose of review: Autosomal dominant hypercholesterolemia is a common cause of cardiovascular disease. In addition to the classic genes that cause hypercholesterolemia, LDLR, APOB and PCSK9 , a new locus has emerged as a...